Reinhard Kandera
Finanzdirektor/CFO bei HOOKIPA PHARMA INC.
Vermögen: 34 732 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Thomas Lingelbach | M | 60 |
Intercell AG
 Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria.
Elatos GmbH
Vaccines Holdings Sweden AB
 Vaccines Holdings Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014. | 18 Jahre |
| Franck Grimaud | M | 58 |
Vaccines Holdings Sweden AB
Vaccines Holdings Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014. | 11 Jahre |
| Roman Necina | M | 56 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 10 Jahre |
| Timothy Reilly | M | 50 | 2 Jahre | |
| Julie O'Neill | F | 58 | 6 Jahre | |
| Jan van de Winkel | M | 63 | 7 Jahre | |
| David Lawrence | M | 61 |
Vaccines Holdings Sweden AB
Vaccines Holdings Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014. | 7 Jahre |
| David Kaufman | M | 51 | 5 Jahre | |
| Klaus Orlinger | M | 46 | 12 Jahre | |
| Tony Melckenbeek | M | - | - | |
| Mary Coelho | F | 62 | 1 Jahre | |
| Jörn Aldag | M | 65 | 8 Jahre | |
| Laetitia Bachelot-Fontaine | F | - | 11 Jahre | |
| Malte Peters | M | 61 | 1 Jahre | |
| Lars Åke Gunnar Hallman | M | 82 |
Vaccines Holdings Sweden AB
Vaccines Holdings Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014. | 10 Jahre |
| F. Weller Meyer | M | 81 | 18 Jahre | |
| Frédéric Jacotot | M | 60 |
Vaccines Holdings Sweden AB
Vaccines Holdings Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014. | 7 Jahre |
| Robert C. Seid | M | - | 16 Jahre | |
| Kai Chen | M | - | - | |
| Victor Paulus | M | - | 6 Jahre | |
| Richard Douglas | M | 71 | 22 Jahre | |
| Thomas Martin Vernon | M | 85 | 18 Jahre | |
| Sarah A. Frech | M | - | - | |
| Jin Sook Chung | F | - | 27 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Michel Gréco | M | 80 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 13 Jahre |
| Hans Lennart Rudolf Wigzell | M | 86 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 3 Jahre |
| Graziano Seghezzi | M | 55 | 10 Jahre | |
| Christine Baker | F | 58 | 5 Jahre | |
| Jean-Charles Soria | M | 53 | - | |
| Ralf Clemens | M | 71 | 3 Jahre | |
| Daniel Courtney | M | - | - | |
| Christoph S. Lengauer | M | 59 | 4 Jahre | |
| Daniel D. Pinschewer | M | 49 | 8 Jahre | |
| Nina Waibel | F | - |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 3 Jahre |
| James Sulat | M | 73 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 8 Jahre |
| Katia Schlienger | M | 62 | 2 Jahre | |
| Alexander Ullrich von Gabain | M | 73 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 16 Jahre |
| Ernst-Günter Afting | M | 80 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 14 Jahre |
| Sander J. van Deventer | M | 69 | 9 Jahre | |
| Thomas D. Szucs | M | 64 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 2 Jahre |
| Anders Lilja | M | - | 7 Jahre | |
| Mustapha Bakali | M | 62 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 6 Jahre |
| Michael Kelly | M | 67 | 4 Jahre | |
| Frédéric Legros | M | 48 | - | |
| Gwenaelle Kerforn | F | - | 3 Jahre | |
| Manfred Tiefenbacher | M | - | - | |
| Igor Matushansky | M | 51 | 5 Jahre | |
| Louisa Shaw-Marotto | F | 56 | 4 Jahre | |
| Paul-Henri Lambert | M | 85 | 8 Jahre | |
| David Ebsworth | M | 69 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 8 Jahre |
| Matthew Beck | M | - | 4 Jahre | |
| Majid Mehtali | M | 63 | - | |
| Gregory Glenn | M | 70 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 2 Jahre |
| Katherine Cohen | M | - |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 11 Jahre |
| Gerald Strohmaier | M | - |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | - |
| Werner Lanthaler | M | 56 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 9 Jahre |
| Gerd Zettlmeissl | M | 68 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 10 Jahre |
| Anne-Sophie Herelle | F | 43 | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 35 | 60,34% |
| Österreich | 16 | 27,59% |
| Frankreich | 11 | 18,97% |
| Schweden | 5 | 8,62% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Reinhard Kandera
- Persönliches Netzwerk
